Back to top
more

Chemomab Therapeutics (CMMB)

(Delayed Data from NSDQ)

$1.02 USD

1.02
64,333

-0.01 (-0.98%)

Updated Aug 4, 2025 12:27 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

KURA Stock Rises More Than 15% This Past Week: Here's Why

by Zacks Equity Research

Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant AML.

Zacks Equity Research

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

by Zacks Equity Research

Tempest jumps after EMA grants orphan drug status to its liver cancer candidate, amezalpat, based on positive study data.

Zacks Equity Research

MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study

by Zacks Equity Research

Merck reports promising response rates for its ADC zilovertamab vedotin in relapsed DLBCL and KRAS inhibitor MK-1084 in solid tumors.

Zacks Equity Research

NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study

by Zacks Equity Research

Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.

Zacks Equity Research

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

by Zacks Equity Research

Candel stock rises as FDA grants RMAT tag to CAN-2409 after phase III success in prostate cancer. BLA submission is planned at the end of 2026.

Zacks Equity Research

RCKT Stock Tanks on Patient Death in Danon Disease Study

by Zacks Equity Research

Rocket Pharmaceuticals plunges after a patient death in its Danon disease study, prompting a voluntary dosing pause. The FDA puts a clinical hold on the study.

Zacks Equity Research

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

by Zacks Equity Research

TEVA starts IND-enabling studies for BD9, a dual-targeting multibody for asthma and eczema. Shares rise on the news.

Zacks Equity Research

Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Chemomab Therapeutics (CMMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy?

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Zacks Equity Research

Here's Why Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Chemomab Therapeutics Ltd. Sponsored ADR (CMMB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC

by Zacks Equity Research

The FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises.

Zacks Equity Research

Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA

by Zacks Equity Research

Intercept's (ICPT) new drug application (NDA) for obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis gets accepted by the regulatory body in the United States.

Zacks Equity Research

Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why

by Zacks Equity Research

Intercept (ICPT) gains 12% in the last six months on Ocaliva's positive performance and encouraging pipeline progress.

Zacks Equity Research

The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax

by Zacks Equity Research

Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax are included in this Analyst Blog.

Zacks Equity Research

Biotech Stock Roundup: GERN Surges on Study Data, PHAT, VERA Offer Updates & More

by Zacks Equity Research

Updates from Geron (GERN) and VERA are the key highlights from the biotech sector during the past week.

Zacks Equity Research

Chemomab (CMMB) Mid-Stage Study for NASH Meets Primary Goal

by Zacks Equity Research

Chemomab's (CMMB) phase II study evaluating CM-101 in NASH patients met its primary endpoint of safety and tolerability.

Zacks Equity Research

New Strong Sell Stocks for March 14th

by Zacks Equity Research

AVYA, BGS, and CMMB have been added to the Zacks Rank #5 (Strong Sell) List on March 14, 2022.